Catastrophic episodes of MeHg poisoning due to accidents or to the consumption of food contaminated by high concentrations of MeHg have been described (1,2). Because ingested MeHg is almost completely absorbed from the digestive tract and easily accumulates in the brain, chronic low-level dietary intake of MeHg also poses a significant toxicologic problem. Excessive MeHg intake has been reported in fish-eating communities in Greenland, the Faroe Islands, the Seychelles, the Madeira Basin (in the Amazon region), and New Zealand (3-5). There is concern about the risks to human nervous system development associated with such exposures. Several observations indicate that the immature brain is highly susceptible to MeHg toxicity (6). In prenatal exposure, deficits in infant brain development have been associated with MeHg levels that cause few, if any, symptoms or signs of toxicity in adults (7).
Methylmercury (MeHg) affects several parameters of cholinergic function. These alterations are thought to play a role in MeHg neurotoxicity. In vitro experiments have indicated that MeHg acts as a strong competitive inhibitor of radioligand binding to muscarinic cholinergic receptors (mAChRs) in rat brain. Furthermore, rat brain mAChRs share several pharmacologic characteristics of similar receptors present on lymphocytes. Using the muscarinic antagonist [3H]quinuclidinyl benzilate (QNB) to label receptors, we investigated the in vivo interactions of MeHg with rat brain mAChRs. We also investigated whether MeHg-induced central mAChR changes are reflected by similar alterations in splenic lymphocytes. Exposure to low doses of MeHg-0.5 or 2 mg/kg/day in drinking water-for 16 days significantly increased (20-44% of control) mAChRs density (BE ) in the hippocampus and cerebellum without affecting receptor affinity (Kd). The effect of MeHg did not occur immediatelry it was not apparent until 2 weeks after the termination of treatiment. No significant changes in [3H]QNB binding were observed in the cerebral cortex. In splenic lymphocytes, mAChR density was remarkably increased (95-198% of control) by day 14 of MeHg exposure and remained enhanced 14 days itfter the cessation of treatment. These results suggest up-regulation of mAChRs in selected brain regions (hippocampus and cerebellum) after prolonged low-level ingestion of MeHg in rats. These cerebral effects are delayed in onset and are preceded by a marked increase in density of mAChRs on lymphocytes. In chronic MeHg exposure, peripheral lymphocytes may represent a sensitive target for the interaction of MeHg with mAChRs and, therefore, may be predictive indicators of later adaptive response involving cerebral mAChRs. Additionally, the effect of MeHg on lymphocyte mAChRs in vivo indicates that this receptor system should be investigated fiurther as a possible target for MeHg immunotoxicity. Key words: biomarker, brain, cholinergic system, lymphocyte, methylmercury, muscarinic receptor, neurotoxicity. Environ Health Perspect 108: 29-33 (2000) .
[Online 2 December 1999] /ttp://ehpnetl.niehs.nih.gov/docs/2000/108p29-33coccini/abstract.htl Methylmercury (MeHg) is a ubiquitous and hazardous environmental contaminant. Catastrophic episodes of MeHg poisoning due to accidents or to the consumption of food contaminated by high concentrations of MeHg have been described (1, 2) . Because ingested MeHg is almost completely absorbed from the digestive tract and easily accumulates in the brain, chronic low-level dietary intake of MeHg also poses a significant toxicologic problem. Excessive MeHg intake has been reported in fish-eating communities in Greenland, the Faroe Islands, the Seychelles, the Madeira Basin (in the Amazon region), and New Zealand (3) (4) (5) . There is concern about the risks to human nervous system development associated with such exposures. Several observations indicate that the immature brain is highly susceptible to MeHg toxicity (6) . In prenatal exposure, deficits in infant brain development have been associated with MeHg levels that cause few, if any, symptoms or signs of toxicity in adults (7) .
Research data indicate that the cholinergic Surstem is one of multiple targets for MeHg neurotoxicity. In vitro MeHg inhibits choline uptake and choline acetyltransferase (ChAT) activity while exerting both stimulatory and inhibitory effects on acetylcholine (ACh) release from central (8) and peripheral (9) nerve endings. Additionally, MeHg inhibits radioligand binding to brain cholinergic (nicotinic and muscarinic) receptors in a competitive manner (10) (11) (12) . The results of in vivo studies support these observations. Longterm administration of MeHg slightly but uniformly decreases cerebral ChAT activity (13) . As a result, the rate of ACh synthesis and the levels of regional ACh are decreased (14, 15) . In rats, prenatal exposure to MeHg reduced muscarinic binding in the developing brain (16) .
Radioligand binding studies have also documented the presence of cholinergic muscarinic receptors (mAChRs) in nonexcitable tissues, for example, splenic or circulating lymphocytes, from both rats (17, 18) and humans (19, 20) . Rat lymphocyte mAChRs share several pharmacologic characteristics of similar receptors present in brain tissue (21) .
Muscarinic binding was modulated by cholinergic and anticholinergic compounds in a similar manner in brain and lymphocytes (22) . In comparative assays using V3H]quinuclidinyl benzilate ([3H]QNB) to label mAChRs, a 14-day exposure to the organophosphate pesticide disulfoton (an acetylcholinesterase inhibitor) caused a significant decrease (25-35%) in mAChRs density in brain areas (cerebral cortex, hippocampus, striatum, and medulla pons), as well as in lymphocytes (23) . During disulfoton exposure, the decline of mAChR density in lymphocytes paralleled those observed in brain (23) . These findings suggest that lymphocytes may serve as peripheral markers of the central mAChR changes induced by xenobiotics. Application of mAChR assays using peripheral blood lymphocytes has recently been described in patients with disease states that are likely associated with alteration of the central cholinergic receptors (24, 25) .
There is growing evidence from animal and cell culture studies that MeHg may adversely affect the immune system (26) . Low concentrations of MeHg (0.6-5 pM) cause dose-dependent changes and cell death in human T cells (26) . These effects are apparently induced by MeHg by apoptotic mechanisms that also appear to play a major role in MeHg neurotoxicity (27 and Hank's buffer in a total volume of 0.5 mL in plastic tubes. After 60 min incubation under gentle shaking at 27°C, the reaction was stopped by adding 3 mL ice-cold phosphate-buffered saline (PBS); samples were rapidly filtered through Whatman GF/C filters (Whatman, Maidstone, Kent, UK) using a Brandel cell harvester (Emanuele Mires, Milan, Italy) and washed three times with 3 mL ice-cold PBS. Filters were then air dried and counted for radioactivity in 3 mL Biofluor in a Packard 1900 CA scintillation counter (Packard, Milan, Italy). Atropine In contrast with the effect on receptor binding in brain tissue, the changes induced by MeHg in lymphocytes were present immediately at the end of the exposure period and were still observable 14 days after termination of treatment (Figure 2) . Analyses of data from saturation curves of [3H]QNB binding (Figure 3) clearly illustrate the different pattern and regional selectivity of the response to MeHg with changes in receptor density that developed earlier and were more pronounced in lymphocytes than in brain tissue.
As in the brain, the affinity of lymphocyte mAChRs (Kd) was not affected by MeHg treatment, and the Hill coefficients (nH) were close to unit (0.92-1.14) in both control and MeHg-treated rats (Tables 1 and 2 ).
Discussion
In this study, prolonged exposure of rats to MeHg at a daily dose as low as 0.5 mg/kg caused molecular changes involving Environmental Health Perspectives * Volume 108, Number 1, January 2000 cholinergic receptors in brain and lymphocytes. These findings are discussed in relation to the effects of MeHg on the nervous system and in relation to perspectives in the area of markers of subclinical MeHg toxicity. The cholinergic system and MeHg neurotoxicity. MeHg ingestion caused selective increases in mAChR density in two rat brain regions (hippocampus and cerebellum) without affecting receptor affinity. These findings agree with earlier in vitro studies describing the alteration of muscarinic receptor binding characteristics in rat brain preparations treated with MeHg (12) . The MeHg action on cerebral mAChRs was delayed in onset. Increase in receptor density was not demonstrable immediately after termination of exposure but was invariably seen in the animals examined 2 weeks after the end of exposure.
Because cholinergic systems play an important role in learning and memory processes (35) , the increased mAChR density caused by MeHg in brain tissue may be a deleterious process. The MeHg-induced changes in cerebral mAChR density were regionally specific. The cerebellum, a primary target for MeHg neurotoxicity, was the most susceptible area showing delayed receptor changes even at the lower 0.5 mg/kg/day MeHg dose. Hippocampal mAChR density was increased 14 days after exposure to 2 mg/kg/day MeHg, whereas cerebrocortical receptors were not affected at either dosing regimen. Several studies report selective or focal brain damage as a typical response to MeHg in both laboratory animals (27) and humans (1) . Autoradiographic experiments in mice have shown that MeHg accumulates preferentially in the hippocampus and cerebellum (36) (37) (38) , suggesting that the observed cerebral mAChR changes correlate to the concentration of MeHg in particular brain regions.
Experiments indicating that MeHg slowly accumulates in the rat brain during continuous low-level exposure provide one explanation for the late appearance of cerebral mAChR changes in the MeHg-treated rats (39) . It has also been suggested that the development of some neurologic effects of MeHg depends not only on the ability of MeHg to attain effective concentrations in brain tissue but also on the length of time they are maintained (40) . The absorbed MeHg requires several weeks for removal from the rat brain (16, 39) . Adaptive changes involving mAChRs in the target organ may occur after prolonged overexposure to MeHg. Neurotransmitter receptors are regulated by homeostatic mechanisms that compensate for changes in the amount of agonist or antagonist to which they are exposed (22, 23) . For example, although mAChRs overstimulation induces a receptor density decrease (down-regulation), prolonged treatments with muscarinic antagonists (e.g., atropine) cause receptor increase (up-regulation) and supersensitivity to muscarinic agonists (22) . Thus, the delayed effect of MeHg in the rat brain might be attributable to a combination of factors. Gradual accumulation of MeHg in brain tissue and up-regulation of cerebral mAChRs may occur during chronic MeHg exposure to compensate for early stage effects such as a) MeHg-induced inhibition of ACh synthesis (13) and consequent reduction of brain ACh levels (14, 15) , and b) direct (atropinelike) competitive antagonism by MeHg on mAChRs (10) (11) (12) . It is increasingly evident that adaptation of neurotransmitter receptors may be a primary mechanism mediating the long-term actions of drugs and chemicals in the central nervous system (41) .
Our findings in adult rats differ from observations in the immature rat brain where MeHg decreased and did not increase [3H]QNB binding (16) . In pregnant rats, a single dose of 8 mg/kg MeHg by gavage on day 15 of gestation temporarily reduced the density of cerebrocortical mAChRs in the offspring (16) . The effect was observed in the brain of 14-and 21-day-old animals but was not present in 60-day-old rats in which the concentrations of mercury in the cerebral cortex had returned to normal. In the developing rat brain, mAChRs appear between gestational days 16 and 18 (42) . Their density increases gradually after birth, reaching adult levels at approximately 30-45 days of age (43, 44) . Therefore, it seems that MeHg inhibits the development of mAChRs when administered before they appear. Perhaps the postulated up-regulation mechanism, which in the adult compensates for the complex interactions of MeHg with the cholinergic system, is not functional in the immature brain.
Muscarinic cholinergic receptors as biomarkers. It is increasingly evident that biochemical and molecular parameters similar to those involved as targets for toxicants in the central nervous system are also present in more easily accessible tissues, for example, peripheral blood cells (45) . Examples include neurotransmitter metabolizing enzymes, second messengers, high-affinity uptake systems, and neurotransmitter receptors such as mAChRs expressed not only in the nervous system but also in peripheral blood lymphocytes in rats (18) and in humans (20) . Because circulating lymphocytes can be easily and ethically obtained from humans and because they can be sampled repeatedly over prolonged chemical exposure, strategies using these peripheral samples as surrogate indicators offer the advantage of exploring early effects of neurotoxicants by convenient noninivasive methods (46) . In rats exposed to MeHg, significant increases in mAChR density were found not only in hippocampus and cerebellum but also in splenic lymphocytes. The receptor increase in lymphocytes was even more pronounced (up to 198% vs. 20-44%) and more rapid in onset than that in brain tissue. There was no temporal correlation for the receptor changes occurring in MeHg response in brain and lymphocytes. The reason for this discrepancy is not evident. In rats, prolonged low-level administration of MeHg caused higher (up to 10-fold) mercury levels in the spleen than in brain (47) . In chronic exposure, the effective MeHg concentration required to modify mAChRs density may be more rapidly attained in peripheral lymphocytes than in the less accessible brain tissue where the rates of access and accumulation of MeHg are limited by the blood-brain barrier.
Muscarinic receptors belong to a multigenic family that codes for at least five receptor subtypes (48) . At control levels, [3H]QNB displayed a lower affinity in lymphocytes than in brain tissue, confirming previous observations (21) . A possible explanation for this finding would be that the subtypes of mAChRs expressed in lymphocytes are different than in brain. Current knowledge of the interaction of MeHg with these heterogeneous receptor subpopulations is limited. In rat brain, MeHg affects binding characteristics of mAChRs of the Ml and M2 subtypes (12) . M2 receptors have been identified in lymphocytes from rats (22, 46, 49) and humans (20, 50) . Studies examining the interaction of MeHg with subtypes of lymphocyte muscarinic receptors would be helpful to establish whether the muscarinic cholinergic recognition sites expressed in peripheral tissues are representative of the corresponding molecular parameters present in the central nervous system.
The interaction of MeHg with mAChRs in lymphocytes may have important implications not only in relation to biomarkers but also from an immunologic viewpoint. The immunotoxic potential of mercury compounds has become a subject of great interest (51) . Lymphocyte mAChRs respond to cholinergic stimulation with altered membrane fluidity and modification of immune function (52).
In conclusion, prolonged ingestion of low doses of MeHg in rats causes subtle molecular changes with adaptive imbalance of mAChRs in the hippocampus and cerebellum, perhaps through an up-regulation mechanism. The onset of the effect of MeHg is delayed and is preceded by a marked increase in density of mAChRs expressed in splenic lymphocytes. Because 
